Sign In
Buy COEP
$10.99
+0 (+0%)
At Close: Jul 22, 2026
Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform
10:31am, Wednesday, 13'th Apr 2022
Coeptis Therapeutics Inc (OTC: COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ: STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5)
